Using RNA Analytics, Bioinformatics, and Machine Learning/AI
AMPEL Genomic Platform (AGP®) and
clinical genomic blood tests for patients:
Evaluate disease status
Identify molecular pathways
Predict drug options
Precise Patient Solutions
AMPEL Genomic Platform (AGP®), Bioinformatic Tools and Machine Learning Algorithms (AI/ML)
Step 1:
Create A Genomic Fingerprint
Comprehensive RNA analytics of gene expression from blood or biopsy to determine disease activity, molecular pathways and drug options.
Step 2:
Analyze The Fingerprint With ML/AI
Covers >95% of all known genes and is disease agnostic.
Step 3:
Provide Decision Making Support
Status of a patient’s disease and most appropriate treatment options at the time of the test are provided in a report.
Step 4:
Market ready and Reproducible
First-in-class CLIA-certified gene-based Lab Developed Test (LDT).
Key Stats
Lead product LuGENE® expected Q4 2022. DermaGENE® expected Q4 2023.
Products for other indications available for partnering.
95%
coverage of all known genes and is disease agnostic
15,000+
autoimmune and normal patient gene expression profiles with rich clinical information – world’s largest for Lupus
22+
technology patents filed & pending with the freedom to operate
15+
pharma customers validate the technology
5+
additional autoimmunity products in development
About the Founders
AMPEL’s co-founders, Amrie Grammer and Peter Lipsky, are internationally recognized scientists and successful entrepreneurs, having founded and managed AMPEL to profitability consistently for 5+ years. Their success has been a combination of world-class science with business acumen. Dr. Grammer was elected to the class of 2021 of SIBF (Society of International Business Fellows), an organization of 1400 in 45 countries world-wide and was awarded a Virginia SBIG grant from AMPEL’s first investment round. She is a second term board member of Virginia Bio. View Executive Team.
Peer-Reviewed Journal Articles
Published in Internationally Recognized Peer-Reviewed Journals
The pathogenesis of systemic lupus erythematosus: Harnessing big data to understand the molecular basis of lupus
COVID-19 Patients Exhibit Unique Transcriptional Signatures Indicative of Disease Severity
Altered expression of genes controlling metabolism characterizes the tissue response to immune injury in lupus
Transcriptomics data: pointing the way to subclassification and personalized medicine in systemic lupus erythematosus
Analysis of Trans-Ancestral SLE Risk Loci Identifies Unique Biologic Networks and Drug Targets in African and European Ancestries
Deconvoluting the heterogeneity of SLE: The contribution of ancestry
Medelian Randomization and Pathway Analysis Demonstrate Shared Genetic Associations Between Systemic Lupus Erythematosus and Coronary Artery Disease
Machine learning reveals distinct gene signature profiles in lesional and nonlesional regions of inflammatory skin diseases
Recent News
New blood test could prevent premature death from heart attacks and stroke
You won’t find test tubes or chemicals at Ampel Biosolutions. Instead, the company uses computers to study huge amounts of medical information – to identify genes responsible for auto-immune, kidney, skin, neurologic and infectious diseases.
New Blood Test to Help Physicians Prevent Major Cardiovascular Events in Women with Lupus
Now, a genetic precision medicine test for lupus patients could save lives by predicting heart disease before it happens and providing decision support for prophylactic therapies.
New Test Helps Predict Heart Disease in Lupus Patients
AMPEL BioSolutions has announced that its genetic precision medicine test for lupus patients could predict heart disease and provide decision support for prophylactic therapies.Â
AMPEL unveils new genetic test for cardiovascular disease in lupus patients
The CardioGENE lab test identifies inherited genetic markers in blood samples which drive pathways to prevent cardiovascular issues with prophylactic targeted treatment
Early Genetic Testing Predicts Heart Disease and Novel Therapies for Women with Lupus
AMPEL BioSolutions today announced a genetic precision medicine test for lupus patients that could save lives by predicting heart disease before it happens and providing decision support for prophylactic therapies.
Heart Disease Blood Test
Ampel Bio-Solutions is working on a blood test that can find out if a person carries traits that may put them at higher risk of developing heart disease.
Lupus, coronary artery disease share genetic risk factors; data may lead to early testing
Researchers have identified shared genetic risk factors for systemic lupus erythematosus and coronary artery disease, according to data published in Cell Reports Medicine.
Charlottesville company creates early genetic test to predict heart disease
It’s a breakthrough discovery for the first-time identifying risk factors in inflammation and the immune system that lead to cardiovascular events. Outside the traditional risk factors of smoking, high fat diet and sedentary lifestyle. Cardio Gene could be a game changer
Early Genetic Testing Predicts Heart Disease And Novel Therapies For Women With Lupus
AMPEL BioSolutions today announced a genetic precision medicine test for lupus patients that could save lives by predicting heart disease before it happens and providing decision support for prophylactic therapies.
In Conversation: Dr. Amrie Grammer, Co-founder, President and Chief Scientific Officer, AMPEL Biosolutions
These are exciting times for the AMPEL team. BioBuzz thought it was a great time to catch up with AMPEL’s Co-founder, President, and Chief Scientific Officer Dr. Amrie Grammer to discuss her founder’s journey and AMPEL’s promising future.